同源康医药-B(02410)

39.150+1.350+3.57%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
同源康医药-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。
- 09-27
  半年度报告
  2024中期报告
  2024中期报告
- 08-30
  半年度报告
  截至2024年6月30日止六个月中期业绩公告
  截至2024年6月30日止六个月中期业绩公告
- 08-12
  股份发售
  全球发售
  全球发售

分时
5日
日
周
月

最高

40.750

今开

37.000

量比

0.21

最低

37.000

昨收

37.800

换手率

0.03%

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"fillings","symbol":"02410","data":{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":39.15,"timestamp":1732694936027,"preClose":37.8,"halted":0,"volume":60500,"delay":0,"floatShares":193000000,"shares":370835818,"eps":-1.4221634,"marketStatus":"未开盘","marketStatusCode":0,"change":1.35,"latestTime":"11-27 16:08:56","open":37,"high":40.75,"low":37,"amount":2353850,"amplitude":0.099206,"askPrice":39.2,"askSize":500,"bidPrice":37.95,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.5069662297888236,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732757400000},"adr":0,"listingDate":1724083200000,"adjPreClose":37.8,"openAndCloseTimeList":[[1732671000000,1732680000000],[1732683600000,1732694400000]],"volumeRatio":0.2071917807864398,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":null,"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"18653724","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDa8ffoZeXZ","pdf_url":"https://static.tigerbbs.com/3bf20bbd552f4fde9768a429aa07ab21","pub_time":1727426700000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024中期报告","symbol":"02410","title":"2024中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0927/2024092700920_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-27 16:45","pubTimestamp":1727426700,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18559041","market":"hk","labels":[],"media":"港交所","original_id":"N.HKJ6zpjRgpMT","pdf_url":"https://static.tigerbbs.com/be1fa360987748aa9d1e9642550fe2d3","pub_time":1725007620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年6月30日止六个月中期业绩公告","symbol":"02410","title":"截至2024年6月30日止六个月中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083000942_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-30 16:47","pubTimestamp":1725007620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18458575","market":"hk","labels":[],"media":"港交所","original_id":"N.HK8CzhcJraXG","pdf_url":"https://static.tigerbbs.com/52b2dfd43b1b4917960f378086db6cae","pub_time":1723414560000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"02410","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0812/2024081200006_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2024-08-12 06:16","pubTimestamp":1723414560,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"stockEarnings":[{"period":"1week","weight":0.35},{"period":"1month","weight":0.267},{"period":"3month","weight":0.8083},{"period":"6month","weight":2.2355},{"period":"ytd","weight":2.2355}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":-0.0484},{"period":"3month","weight":0.1021},{"period":"6month","weight":0.0843},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1499}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"aProfile":null}}}